Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate.
COVID-19
GCxGC-MS
breath analysis
metabolomics
noninvasive analysis
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
06 Dec 2021
06 Dec 2021
Historique:
received:
10
11
2021
revised:
30
11
2021
accepted:
01
12
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath's biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.
Identifiants
pubmed: 34940605
pii: metabo11120847
doi: 10.3390/metabo11120847
pmc: PMC8708149
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AGING Project-Department of Excellence-369 DIMET, Università del Piemonte Orientale, MIUR ITALY and by Regione Piemonte FSC Azione 173 370 INFRA-P2 COVID, MS4CoV
ID : 377-1
Références
Eur Respir J. 2017 Apr 26;49(4):
pubmed: 28446552
J Anal Methods Chem. 2016;2016:6853591
pubmed: 27957383
Periodontol 2000. 2020 Jun;83(1):234-241
pubmed: 32385873
J Breath Res. 2020 Jul 21;14(4):041001
pubmed: 32531777
ERJ Open Res. 2021 Jul 05;7(3):
pubmed: 34235208
Antimicrob Agents Chemother. 1987 Jan;31(1):27-31
pubmed: 3032090
J Proteomics. 2019 Sep 15;207:103450
pubmed: 31323423
J Anim Sci Biotechnol. 2020 Dec 8;11(1):114
pubmed: 33292608
EClinicalMedicine. 2020 Dec;29:100609
pubmed: 33134902
ACS Infect Dis. 2021 Sep 10;7(9):2596-2603
pubmed: 34319698
Sci Rep. 2018 Oct 5;8(1):14857
pubmed: 30291257
J Breath Res. 2008 Sep;2(3):037004
pubmed: 21386165
J Anal Test. 2021 Aug 16;:1-11
pubmed: 34422436
AIMS Microbiol. 2020 Jul 3;6(3):183-203
pubmed: 33134740
Tuberculosis (Edinb). 2012 Jul;92(4):314-20
pubmed: 22647661
Sci Rep. 2021 Jul 5;11(1):13796
pubmed: 34226622
J Breath Res. 2016 Feb 11;10(1):016011
pubmed: 26866403
EBioMedicine. 2021 Jan;63:103154
pubmed: 33279860
Anal Chim Acta. 2021 Sep 22;1179:338841
pubmed: 34535255
Mod Pathol. 2020 Nov;33(11):2156-2168
pubmed: 32879413
Biomark Med. 2017 May;11(6):405-407
pubmed: 28617073
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
J Clin Invest. 1984 Oct;74(4):1269-79
pubmed: 6548228
Eur Respir J. 2014 Jul;44(1):188-97
pubmed: 24743964
PLoS One. 2016 Oct 20;11(10):e0164394
pubmed: 27764146
J Anim Sci. 2020 Jun 1;98(6):
pubmed: 32447386
Sci Rep. 2017 May 3;7(1):1421
pubmed: 28469199
Sci Rep. 2019 Dec 11;9(1):18894
pubmed: 31827195
Arch Virol. 2007;152(12):2225-36
pubmed: 17891329
J Breath Res. 2015 Jan 05;9(1):016004
pubmed: 25557917